23 December 2024 in The Korean Journal of Pain
In-Ae Song, Joon Hee Lee, Woong Ki Han, and Francis Sahngun Nahm. Korean J Pain -0001;0:. https://doi.org/10.3344/kjp.24209
23 December 2025 in Pain Medicine
Background: Cancer-related pain management remains challenging, particularly for spinal metastases, in which pain arises from multiple pathological mechanisms. Despite the increasing use of epidural steroid injections (ESI) in clinical practice as part of multimodal pain management, the evidence of their effectiveness in these patients remains limited. Design: A retrospective cohort study. Setting: Three university-affiliated tertiary hospitals in South Korea. Subjects: A total of 123 patients with cancer and radiologically confirmed spinal metastases who underwent ESI between January 2020 and December 2022. Patients were categorized as effective (Group E, ≥50% pain reduction at 1 month, n = 73) or non-effective (Group N, n = 50). Methods: Pain intensity, opioid use, patient satisfaction, repeat procedures, and survival were evaluated at baseline and 1 and 3 months after ESI. In addition, factors influencing the effectiveness of ESI were analyzed. Results: A better performance status (ECOG-PS 1) and lower baseline opioid requirements predicted a favorable ESI response. The Group E maintained pain relief at 3 months with a minimal increase in opioid use, reported higher satisfaction (94.5% vs 6.5%), needed fewer repeat injections (64.4% vs 86.6%), and demonstrated better 6-month survival (78.1% vs 34.0%) than Group N. Conclusion: ESI may be beneficial in reducing pain and attenuating opioid escalation in patients with spinal metastases, especially when the performance status is relatively preserved, and before the initiation of high-dose opioid therapy. These results support early integration of ESI into multimodal cancer pain management strategies.
31 January 2025 in Anesthesia and Pain Medicine
Background: Serotonin syndrome results from the use of serotonergic agents that elevate intrasynaptic serotonin level or excessively activate serotonin postsynaptic receptors. Common serotonergic agents used for pain management include opioids, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants.Case: A 24-year old woman diagnosed with complex regional pain syndrome underwent multidrug therapy for pain management over approximately five years. During this period, changes in diaphoresis severity were noted following adjustments to pain medications. The concurrent use of multiple serotonergic agents, exacerbation of diaphoresis after the addition or dose escalation of opioids, and resolution of symptoms upon discontinuation of duloxetine (Cymbalta®, Lily S.A.) strongly suggest the development of serotonin syndrome.Conclusions: Diagnosing serotonin syndrome without neuromuscular symptoms can be challenging. Careful monitoring of changes in symptoms and signs following medication use is essential in such cases.
1 September 2026 in Journal of Pain Research
Background: Complex regional pain syndrome (CRPS) is a chronic pain disorder characterized by severe and disproportionate symptoms, with incompletely understood mechanisms. Nuclear factor-kappa B (NF-κB), a key transcription factor in neuroinflammation and pain signaling, is upregulated in animal models of CRPS. Botulinum toxin type A (BTA) has analgesic efficacy in neuropathic pain; however, its effect on NF-κB in CRPS has not been evaluated. This study investigated whether BTA attenuates pain and suppresses NF-κB expression in a rat model of CRPS. Methods: A chronic post-ischemia pain (CPIP) model was induced in male Sprague-Dawley rats. After induction, rats were randomly assigned to receive either BTA or normal saline (NS) injection into the plantar surface of the ipsilateral hind paw. A separate sham group underwent anesthesia without CPIP induction or injection. Mechanical thresholds were assessed, and NF-κB expression in the foot and spinal cord was quantified using enzyme-linked immunosorbent assays. Results: Following BTA injection, mechanical thresholds improved significantly compared with the NS group on days 14 and 21 (P = 0.039 and 0.010). NF-κB expression was significantly reduced in the ipsilateral foot (P = 0.009) and spinal cord (P = 0.025) of the BTA group compared with the NS group, whereas contralateral tissues showed no significant differences. Conclusion: These findings suggest an association between reduced NF-κB levels and the analgesic effects of BTA, supporting its potential therapeutic role in CRPS.
11 September 2026 in The Korean Journal of Pain
Joon Hee Lee, Soo Lyeon Choi, Chang-Hoon Koo, and Eun Joo Choi. Korean J Pain -0001;0:. https://doi.org/10.3344/kjp.26106
8 September 2026 in Supportive Care in Cancer
Purpose: Interventional pain procedures (IPPs) are increasingly considered earlier for cancer-related pain, yet the clinical predictors and prognostic relevance of early analgesic response to IPP remain unclear. We aimed to identify predictors of early response and evaluate its implication for 1-year survival outcomes. Methods: This retrospective cohort study included 349 hospitalized cancer patients undergoing their first inpatient IPP. Early analgesic response was defined by changes in daily mean NRS scores and morphine equivalent daily dose (MEDD) over a 48-h peri-procedural period. Based on these criteria, patients were categorized into overall responders and non-responders. Independent predictors of this early response were identified using multivariable logistic regression, and 1-year survival outcomes were evaluated using Kaplan–Meier analysis with the log-rank test and multivariable Cox proportional hazards regression. Results: Among 349 patients, overall responders (25.5%) were independently associated with higher baseline NRS (odds ratio [OR], 2.13; 95% confidence interval [CI], 1.63–2.83; P < 0.001) and lower baseline MEDD (OR, 0.95 per 10-mg increase; 95% CI, 0.92–0.98; P < 0.001). In multivariable Cox regression, early analgesic response was not independently associated with 1-year mortality (adjusted hazard ratio for non-responders vs. overall responders, 1.26; 95% CI, 0.90–1.77; P = 0.176), although univariable analysis indicated a significant survival advantage (log-rank test, P = 0.037). Conclusion: Higher pain intensity and lower opioid use predict a favorable early analgesic response to IPP, suggesting an optimal therapeutic window for cancer-related pain intervention. Early analgesic response to IPP may serve as an exploratory prognostic indicator in patients with cancer-related pain.